Related references
Note: Only part of the references are listed.Efficacy of JAK inhibitors in Crohn's Disease
Gerhard Rogler
JOURNAL OF CROHNS & COLITIS (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease
Silvio Danese et al.
GASTROENTEROLOGY (2019)
Ver(s)ifying the Efficacy of Vedolizumab Therapy on Mucosal Healing in Patients With Crohn's Disease
Lorant Gonczi et al.
GASTROENTEROLOGY (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn's disease
Ahmad Qasem et al.
BMJ OPEN GASTROENTEROLOGY (2019)
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease
Parambir S. Dulai et al.
GASTROENTEROLOGY (2018)
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease
Geert D'Haens et al.
GASTROENTEROLOGY (2018)
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Siddharth Singh et al.
JOURNAL OF CROHNS & COLITIS (2018)
Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators
Ben Van Calster et al.
EUROPEAN UROLOGY (2018)
Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease
Katsuyoshi Matsuoka et al.
PLOS ONE (2018)
Genetic and environmental factors drive personalized medicine for Crohn's disease
Shigeru Oshima et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures
Uni Wong et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer
Yan-qi Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort
Pascal Juillerat et al.
INFLAMMATORY BOWEL DISEASES (2015)
The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis
Wenjuan Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease
Thomas Billiet et al.
JOURNAL OF CROHNS & COLITIS (2015)
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
Gary S. Collins et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
Gary S. Collins et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Early Intervention with Adalimumab May Contribute to Favorable Clinical Efficacy in Patients with Crohn's Disease
Jun Miyoshi et al.
DIGESTION (2014)
Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab
L. M. Medrano et al.
HUMAN IMMUNOLOGY (2014)
High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2014)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Model Selection and Psychological Theory: A Discussion of the Differences Between the Akaike Information Criterion (AIC) and the Bayesian Information Criterion (BIC)
Scott I. Vrieze
PSYCHOLOGICAL METHODS (2012)
Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
Matthias Jurgens et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Assessing the calibration of mortality benchmarks in critical care: The Hosmer-Lemeshow test revisited
Andrew A. Kramer et al.
CRITICAL CARE MEDICINE (2007)
Share Paper
